NTLA

$0.00

(

0.00%

)
Quote details

stock

Intellia Therapeutics Inc

NASDAQ | NTLA

9.52

USD

$0.00

(

0.00%

)

At Close (As of Nov 7, 2025)

$1.32B

Market Cap

-

P/E Ratio

-4.69

EPS

$28.25

52 Week High

$5.90

52 Week Low

HEALTHCARE

Sector

NTLA Chart

Recent Chart
Price Action

NTLA Technicals

Tags:

NTLA Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $48M
Total Revenue $58M
Cost Of Revenue $10M
Costof Goods And Services Sold $10M
Operating Income -$534M
Selling General And Administrative $126M
Research And Development $466M
Operating Expenses $582M
Investment Income Net -
Net Interest Income $48M
Interest Income $48M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $10M
Income Before Tax -$519M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$519M
Comprehensive Income Net Of Tax -
Ebit -$534M
Ebitda -$524M
Net Income -$519M

Revenue & Profitability

Earnings Performance

NTLA Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $1.2B
Total Current Assets $640M
Cash And Cash Equivalents At Carrying Value $189M
Cash And Short Term Investments $189M
Inventory -
Current Net Receivables $8.5M
Total Non Current Assets $551M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $304M
Short Term Investments $412M
Other Current Assets $30M
Other Non Current Assets -
Total Liabilities $319M
Total Current Liabilities $111M
Current Accounts Payable $15M
Deferred Revenue -
Current Debt -
Short Term Debt $20M
Total Non Current Liabilities $208M
Capital Lease Obligations $210M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $210M
Other Current Liabilities $55M
Other Non Current Liabilities -
Total Shareholder Equity $872M
Treasury Stock -
Retained Earnings -$2.2B
Common Stock $10K
Common Stock Shares Outstanding $99M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$349M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $10M
Capital Expenditures $5.8M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $126M
Cashflow From Financing $186M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$519M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $48M
Total Revenue $58M
Cost Of Revenue $10M
Costof Goods And Services Sold $10M
Operating Income -$534M
Selling General And Administrative $126M
Research And Development $466M
Operating Expenses $582M
Investment Income Net -
Net Interest Income $48M
Interest Income $48M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $10M
Income Before Tax -$519M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$519M
Comprehensive Income Net Of Tax -
Ebit -$534M
Ebitda -$524M
Net Income -$519M

NTLA News

NTLA Profile

Intellia Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Intellia Therapeutics, Inc. (NTLA) is a pioneering gene editing company based in Cambridge, Massachusetts, specializing in the development of transformative therapies for genetic disorders using its proprietary CRISPR/Cas9 technology. The company is advancing a diverse pipeline of innovative treatment candidates currently in clinical trials, underscoring its commitment to precision medicine. As a frontrunner in the gene editing landscape, Intellia benefits from a strong intellectual property foundation and strategic collaborations that enhance its growth potential and influence within the biotechnology sector.

BKYI
+51.56%
$0.96
RUBI
+39.37%
$0.31
AZI
-4.05%
$0.09
NVDA
+0.03%
$188.15
ACHR
-7.88%
$8.18
ASST
+4.13%
$1.51
BYND
+16.80%
$1.39
PFE
+0.04%
$24.43
PLUG
+5.57%
$2.65
MSGM
+70.77%
$3.74
TSLA
-3.67%
$429.52
ONDS
+10.66%
$5.81
INTC
+2.38%
$38.13
VHAI
0.00%
$0.00
GRAB
-1.24%
$5.56
F
+1.82%
$13.21
SOFI
+3.86%
$28.21
DNN
-0.39%
$2.54
PLTR
+1.64%
$177.93
AAL
+3.80%
$13.65
BITF
-0.81%
$3.66
AXDX
-61.36%
$0.03
WTO
-7.52%
$0.04
SNAP
+2.49%
$8.21
RIVN
+0.06%
$15.23
NIO
-4.18%
$6.86
T
+0.36%
$24.83
DVLT
+24.26%
$1.69
CHR
+0.15%
$0.06
ETHD
-9.69%
$4.38
RGTI
-1.71%
$33.77
BTG
+2.89%
$3.91
BURU
+3.54%
$0.28
JOBY
+4.05%
$14.90
IREN
-6.83%
$62.38
RXRX
0.00%
$4.62
PRMB
-18.30%
$14.46
AMD
-1.75%
$233.54
MARA
-0.56%
$15.87
ADAP
-15.14%
$0.05
QBTS
+3.90%
$29.50
PBR
+5.93%
$12.86
SOUN
-0.63%
$14.14
IONZ
-6.57%
$3.55
NVTS
-11.26%
$7.84
AAPL
-0.48%
$268.47
KVUE
+2.55%
$16.88
YDKG
-1.56%
$0.05
AMZN
+0.56%
$244.41
BMNR
+7.65%
$40.22
HOOD
+2.58%
$130.36
CIFR
-4.69%
$20.69
MTVA
+6.84%
$0.90
WULF
-2.38%
$13.94
BTBT
+3.63%
$3.14
EOSE
+19.42%
$18.26
DKNG
+8.64%
$30.40
SMR
-6.53%
$30.34
RMBL
+60.50%
$3.21
BAC
-0.16%
$53.20
RIG
+2.05%
$3.98
ABEV
+1.25%
$2.43
ADD
-25.47%
$0.05
TLRY
+2.47%
$1.24
NOK
-0.72%
$6.86
GOOGL
+0.15%
$284.75
GPUS
+0.43%
$0.37
SRM
+53.27%
$10.30
TTD
-6.31%
$43.00
ORGO
+44.73%
$5.63
QS
+4.52%
$16.62
SMCI
-1.42%
$39.76
CMG
+0.09%
$30.59
IONQ
+3.20%
$59.27
PLTZ
+13.94%
$7.11
EPWK
+3.23%
$0.07
FIG
-3.76%
$44.25
VALE
-0.65%
$12.15
WBD
+1.11%
$22.67
MU
-0.17%
$237.92
AMC
-7.50%
$2.40
PTON
+14.15%
$7.66
RF
+2.22%
$24.85
IOVA
-0.43%
$2.29
ELDN
-49.75%
$2.06
MTC
-6.85%
$2.58
META
+0.44%
$621.71
CGC
+7.33%
$1.17
HIMS
-1.18%
$41.03
WLGS
-5.57%
$0.04
BBD
+0.85%
$3.54
HBAN
+1.75%
$15.69
CAN
+5.30%
$1.19
VZ
+0.55%
$40.04
QUBT
-2.20%
$12.86
NGD
+1.58%
$7.03
CLSK
+1.10%
$15.57
ETWO
0.00%
$3.30
AMCR
+1.82%
$8.36
PLTD
-1.59%
$6.78
BKYI
+51.56%
$0.96
RUBI
+39.37%
$0.31
AZI
-4.05%
$0.09
NVDA
+0.03%
$188.15
ACHR
-7.88%
$8.18
ASST
+4.13%
$1.51
BYND
+16.80%
$1.39
PFE
+0.04%
$24.43
PLUG
+5.57%
$2.65
MSGM
+70.77%
$3.74
TSLA
-3.67%
$429.52
ONDS
+10.66%
$5.81
INTC
+2.38%
$38.13
VHAI
0.00%
$0.00
GRAB
-1.24%
$5.56
F
+1.82%
$13.21
SOFI
+3.86%
$28.21
DNN
-0.39%
$2.54
PLTR
+1.64%
$177.93
AAL
+3.80%
$13.65
BITF
-0.81%
$3.66
AXDX
-61.36%
$0.03
WTO
-7.52%
$0.04
SNAP
+2.49%
$8.21
RIVN
+0.06%
$15.23
NIO
-4.18%
$6.86
T
+0.36%
$24.83
DVLT
+24.26%
$1.69
CHR
+0.15%
$0.06
ETHD
-9.69%
$4.38
RGTI
-1.71%
$33.77
BTG
+2.89%
$3.91
BURU
+3.54%
$0.28
JOBY
+4.05%
$14.90
IREN
-6.83%
$62.38
RXRX
0.00%
$4.62
PRMB
-18.30%
$14.46
AMD
-1.75%
$233.54
MARA
-0.56%
$15.87
ADAP
-15.14%
$0.05
QBTS
+3.90%
$29.50
PBR
+5.93%
$12.86
SOUN
-0.63%
$14.14
IONZ
-6.57%
$3.55
NVTS
-11.26%
$7.84
AAPL
-0.48%
$268.47
KVUE
+2.55%
$16.88
YDKG
-1.56%
$0.05
AMZN
+0.56%
$244.41
BMNR
+7.65%
$40.22
HOOD
+2.58%
$130.36
CIFR
-4.69%
$20.69
MTVA
+6.84%
$0.90
WULF
-2.38%
$13.94
BTBT
+3.63%
$3.14
EOSE
+19.42%
$18.26
DKNG
+8.64%
$30.40
SMR
-6.53%
$30.34
RMBL
+60.50%
$3.21
BAC
-0.16%
$53.20
RIG
+2.05%
$3.98
ABEV
+1.25%
$2.43
ADD
-25.47%
$0.05
TLRY
+2.47%
$1.24
NOK
-0.72%
$6.86
GOOGL
+0.15%
$284.75
GPUS
+0.43%
$0.37
SRM
+53.27%
$10.30
TTD
-6.31%
$43.00
ORGO
+44.73%
$5.63
QS
+4.52%
$16.62
SMCI
-1.42%
$39.76
CMG
+0.09%
$30.59
IONQ
+3.20%
$59.27
PLTZ
+13.94%
$7.11
EPWK
+3.23%
$0.07
FIG
-3.76%
$44.25
VALE
-0.65%
$12.15
WBD
+1.11%
$22.67
MU
-0.17%
$237.92
AMC
-7.50%
$2.40
PTON
+14.15%
$7.66
RF
+2.22%
$24.85
IOVA
-0.43%
$2.29
ELDN
-49.75%
$2.06
MTC
-6.85%
$2.58
META
+0.44%
$621.71
CGC
+7.33%
$1.17
HIMS
-1.18%
$41.03
WLGS
-5.57%
$0.04
BBD
+0.85%
$3.54
HBAN
+1.75%
$15.69
CAN
+5.30%
$1.19
VZ
+0.55%
$40.04
QUBT
-2.20%
$12.86
NGD
+1.58%
$7.03
CLSK
+1.10%
$15.57
ETWO
0.00%
$3.30
AMCR
+1.82%
$8.36
PLTD
-1.59%
$6.78

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.